14:04 , Feb 12, 2019 |  BC Innovations  |  Translation in Brief

Storm’s RNA modification software

Storm Therapeutics Ltd. has created an algorithm to extend the use of mass spectrometric data to RNA epigenetics. Making it open source, the company plans to put the algorithm in as many hands as possible...
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
01:04 , Jan 11, 2019 |  BioCentury  |  Finance

Exscientia looks inward

After spending six years building its artificial intelligence drug discovery platform and working with pharma partners, Exscientia Ltd. aims to use the bulk of the $26 million raised in a series B round to build...
21:41 , Jan 10, 2019 |  BC Innovations  |  Translation in Brief

Guided design for CRISPR editing

Separate teams from the Wellcome Sanger Institute and The Francis Crick Institute have developed an algorithm and identified a set of genetic features, respectively, that could help drug developers improve the safety of CRISPR-Cas9-based therapies...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
03:21 , Nov 17, 2018 |  BioCentury  |  Product Development

Betting Combos on Biomarkers

Despite lackluster monotherapy data at SITC from the latest tranche of immunotherapy candidates, drug developers are moving into combination trials with PD-1 and PD-L1 inhibitors based on biomarkers of pharmacodynamic activity. Results from the next...
00:18 , Nov 17, 2018 |  BC Extra  |  Preclinical News

Spotlight co-founder uses CRISPR screen to ID T cell regulator genes for cancer

Spotlight Therapeutics Inc. (Hayward, Calif.) co-founder Alexander Marson and colleagues at University of California San Francisco developed a CRISPR-based screen to identify genes that control T cell replication and immunosuppression, and used the results to...
22:55 , Nov 15, 2018 |  BC Innovations  |  Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
20:30 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Leadiant gets Priority Review voucher

FDA issued a Priority Review voucher to Leadiant Biosciences Inc. The voucher was issued after FDA approved Leadiant's Revcovi elapegademase-lvlr (EZN-2279) to treat pediatric and adult patients with adenosine deaminase severe combined immunodeficiency (see "FDA...